Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...7475767778798081828384...143144»
  • ||||||||||  subasumstat (TAK-981) / Takeda
    Enrollment open, PD(L)-1 Biomarker:  Intratumoral Microdosing of TAK-981 in Head and Neck Cancer (clinicaltrials.gov) -  Sep 2, 2020   
    P1,  N=12, Recruiting, 
    In line with current recommendations of BRAF-testing at the time of stage IV diagnosis, the BRAFV600E-mutation is an important factor for the choice of palliative systemic therapy. Not yet recruiting --> Recruiting
  • ||||||||||  fluorouracil / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono, paclitaxel / Generic mfg.
    Clinical, Journal:  Optic neuritis induced by 5-fluorouracil chemotherapy: Case report and review of the literature. (Pubmed Central) -  Aug 30, 2020   
    Trial primary completion date: Jun 2020 --> Oct 2020 Following his seventh cycle of cetuximab/FOLFIRI, he developed acute onset global headache, nausea and loss of vision in the right eye...Chemotherapy was ceased immediately, and intravenous methylprednisolone (1 g) daily for five days was commenced...Drug-induced optic neuritis, while rare, is associated with cytotoxic medications including methotrexate, cisplatin, carboplatin, vincristine and paclitaxel...No abstract available
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, cyclophosphamide intravenous / Generic mfg.
    Journal, IO Biomarker:  Cyclophosphamide Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage FcγR Expression. (Pubmed Central) -  Aug 29, 2020   
    Here, we showed that (i) BM resistance was not only induced by the tumor but also by the intrinsic BM microenvironment; (ii) CTX treatment overcame both resistance mechanisms by activating macrophage migration and phagocytosis, including significant upregulation of activating Fcγ receptors (FcγRIII and FcγRIV) and downregulating the inhibitory receptor, FcγRIIB; and (iii) CTX synergized with cetuximab (anti-EGFR) and trastuzumab (anti-Her2) in eliminating metastatic breast cancer in the BM of humanized mice. These findings provide insights into the mechanisms by which CTX synergizes with antibody therapeutics in resistant niche-specific organs and its applicability in treating BM-resident tumors.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Oral mucosal organoids as a potential platform for personalized cancer therapy. (Pubmed Central) -  Aug 27, 2020   
    Drug screens reveals selective sensitivity to targeted drugs that are not normally used in the treatment of HNSCC patients. These observations may inspire a personalized approach to the management of HNSCC and expand the repertoire of HNSCC drugs.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
    Clinical, Journal:  Drug-related problems with targeted/immunotherapies at an oncology outpatient clinic. (Pubmed Central) -  Aug 27, 2020   
    Adverse drug events were the most common drug-related problems in patients with cancer. The involvement of a clinical pharmacist improved the identification of drug-related problems and helped optimize treatment outcomes in patients receiving targeted chemotherapy/immunotherapy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Antibody-Based Targeting of Cell Surface GRP94 Specifically Inhibits Cetuximab-Resistant Colorectal Cancer Growth. (Pubmed Central) -  Aug 27, 2020   
    We also demonstrated that GRP94 immunoglobulin G monotherapy significantly reduces HCT116 cell growth more potently compared to cetuximab, without severe toxicity in vivo. Therefore, cell surface GRP94 might be a potential novel therapeutic target in cetuximab-resistant CRC, and antibody-based targeting of GRP94 might be an effective strategy to suppress GRP94-expressing cetuximab-resistant CRC.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Enrollment open, Trial completion date, Trial primary completion date:  SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN (clinicaltrials.gov) -  Aug 27, 2020   
    P2,  N=92, Recruiting, 
    Therefore, cell surface GRP94 might be a potential novel therapeutic target in cetuximab-resistant CRC, and antibody-based targeting of GRP94 might be an effective strategy to suppress GRP94-expressing cetuximab-resistant CRC. Active, not recruiting --> Recruiting | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial primary completion date, Metastases:  LCCC1717: Palbociclib and Cetuximab in Metastatic Colorectal Cancer (clinicaltrials.gov) -  Aug 24, 2020   
    P2,  N=57, Recruiting, 
    This is the first report on biomarkers of SCT in R/M HNSCC. Trial completion date: Jul 2023 --> Jan 2026 | Trial primary completion date: Jul 2020 --> Jan 2023
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer (clinicaltrials.gov) -  Aug 23, 2020   
    P1,  N=24, Recruiting, 
    Trial completion date: Jul 2023 --> Jan 2026 | Trial primary completion date: Jul 2020 --> Jan 2023 Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality? (Pubmed Central) -  Aug 22, 2020   
    Complete response was observed in 15% of patients, partial response in 39% of patients, stable disease in 23% of patients, and progression disease in 15% of patients. In this retrospective analysis, anti-EGFR inhibitors showed to be a suitable addendum to chemotherapy in the I and II line, with an excellent tolerance and safety profile both in I and II line.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
    Journal:  Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. (Pubmed Central) -  Aug 18, 2020   
    Extensive analysis of downstream signaling pathways ruled out on-target toxicities. By overcoming the heterogeneity of drug target availability that frequently characterizes poorly responsive or resistant tumors, clinical application of reversible endocytosis inhibition may considerably improve the clinical benefit of ADCC-mediating therapeutic antibodies.
  • ||||||||||  temuterkib (LY3214996) / Eli Lilly
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer (clinicaltrials.gov) -  Aug 18, 2020   
    P1,  N=245, Recruiting, 
    By overcoming the heterogeneity of drug target availability that frequently characterizes poorly responsive or resistant tumors, clinical application of reversible endocytosis inhibition may considerably improve the clinical benefit of ADCC-mediating therapeutic antibodies. Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
  • ||||||||||  CDX-3379 / Celldex
    Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases:  A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) -  Aug 17, 2020   
    P2,  N=30, Active, not recruiting, 
    We found similar activity with q2w and q1w cetuximab, providing reassurance to clinicians and patients that it is appropriate to continue treating with the q2w schedule. Recruiting --> Active, not recruiting | N=45 --> 30 | Trial primary completion date: Jul 2020 --> Oct 2020
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] ​​Adoptive cell therapy of hematological malignancies using Cytokine-Induced Killer cells retargeted with monoclonal antibodies () -  Aug 15, 2020 - Abstract #ITOCI2020ITOC-I_172;    
    Based on this observation, we investigated whether CIK cells can be specifically retargeted against B-cell malignancies by combination with anti-CD20 mAbs, namely Rituximab® (RTX) and Obinutuzumab® (OBI)...Results The combination with both RTX and OBI significantly increased specific CIK cells lysis against several CD20-expressing lymphoma B cell lines, primary tumors from B-cell lymphoma patients and an established PDX, compared to the combination with a control mAb (cetuximab, CTX)...Conclusions Here we proved that CIK cells can be retargeted with clinical-grade mAbs against CD20-expressing lymphomas. These data indicate that the combination of CIK cells with mAbs can represent a novel approach for the treatment of haematological malignancies.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] ​Adoptive cell therapy of triple negative breast cancer with redirected Cytokine-Induced Killer cells () -  Aug 15, 2020 - Abstract #ITOCI2020ITOC-I_155;    
    The antigen-specific mAb favored tumor and metastasis tissue infiltration by CIK cells, and in particular led to an enrichment of the CD16a+ subset. Conclusions Data highlight the potentiality of a novel immunotherapy approach where a non-specific cytotoxic cell population can be converted into tumor-specific effectors with clinicalgrade antibodies, thus providing not only a therapeutic option for TNBC but also a valid alternative to more complex approaches based on chimeric antigen receptor-engineered cells.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] Dual signalling protein 107 triggers innate and adaptive immune response towards tumour cells () -  Aug 15, 2020 - Abstract #ITOCI2020ITOC-I_81;    
    DSP107 is a first-in-class drug candidate that can be used as a monotherapy or in combination with tumor-targeting monoclonal antibodies to trigger induction of anti-cancer immunity. DSP107 is currently tested in IND-enabling studies and clinical development is planned to commence in 2020.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal:  The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells. (Pubmed Central) -  Aug 15, 2020   
    Finally, we analyzed the limitations of EGFR monoclonal antibody therapy, and discussed the current strategies overcoming EGFR related drug resistance. This review will help us better understand the latest battles between EGFR monoclonal antibodies and resistant tumor cells, and the future directions to develop anti-tumor EGFR monoclonal antibodies with durable effects.